Kepler Cheuvreux Suisse SA Takes Position in Stryker Corporation $SYK

Key Points

• Kepler Cheuvreux Suisse SA bought 75,621 shares of Stryker valued at about $27.95 million in Q3, making the stock ~1.5% of its portfolio and its 18th largest holding.
• Director Ronda E. Stryker sold 250,000 shares for roughly $90.73 million, cutting her stake by 9.23%; insiders now own about 5.20% of the company.
• Stryker beat Q4 estimates with $4.47 EPS (vs. $4.40 expected) and $7.17 billion in revenue (up 11.4% YoY), and declared a quarterly dividend of $0.88 per share (1.0% yield).

Kepler Cheuvreux Suisse SA bought a new stake in shares of Stryker Corporation (NYSE:SYK - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 75,621 shares of the medical technology company's stock, valued at approximately $27,952,000. Stryker accounts for approximately 1.5% of Kepler Cheuvreux Suisse SA's portfolio, making the stock its 18th largest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Clayton Financial Group LLC bought a new stake in Stryker in the third quarter valued at $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker during the second quarter valued at about $28,000. Kilter Group LLC bought a new position in shares of Stryker during the 2nd quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in shares of Stryker during the 2nd quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in shares of Stryker in the 3rd quarter valued at about $34,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.20% of the company's stock.

Stryker Price Performance

Shares of NYSE SYK opened at $358.83 on Wednesday. The stock has a market cap of $137.32 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 2.14 and a beta of 0.85. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $404.87. The firm's 50-day simple moving average is $365.82 and its 200 day simple moving average is $368.46.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts' consensus estimates of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company's revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $4.01 EPS. As a group, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's dividend payout ratio is 41.90%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SYK. Wells Fargo & Company upped their price target on Stryker from $452.00 to $456.00 and gave the stock an "overweight" rating in a research note on Friday, November 14th. BTIG Research raised their price objective on Stryker from $410.00 to $412.00 and gave the company a "buy" rating in a research note on Friday, January 30th. UBS Group boosted their price objective on Stryker from $386.00 to $400.00 and gave the company a "neutral" rating in a report on Tuesday, February 24th. Citizens Jmp raised Stryker from a "market perform" rating to an "outperform" rating and set a $440.00 target price on the stock in a research report on Friday, December 19th. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $435.00 price target on shares of Stryker in a research report on Friday, November 14th. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $428.61.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.